{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-21-000004","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.768651+00:00","generated_at":"2026-06-29T17:10:29.345099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nautilus Biotechnology Q2 2021 net loss of $10.7M; raised $345.5M in business combination","bullets":["Completed business combination with ARYA Sciences, receiving gross proceeds of $345.5M.","Q2 2021 operating expenses $10.7M (up 215% YoY); net loss $10.7M vs $3.4M in Q2 2020.","Cash and investments $388.4M as of June 30, 2021.","Appointed Emma Lundberg, Ph.D. to Scientific Advisory Board.","Planning platform commercialization in late-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-21-000004","json":"https://secwatch.observer/filing/0001808805-21-000004.json","markdown":"https://secwatch.observer/filing/0001808805-21-000004.md","text":"https://secwatch.observer/filing/0001808805-21-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880521000004/0001808805-21-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880521000004/naut-20210810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T17:10:29.345099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}